News

US government agency to investigate FDA over rofecoxib

BMJ 2004; 329 doi: 10.1136/bmj.329.7472.935 (Published 21 October 2004)
Cite this as: BMJ 2004;329:935.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jeanne Lenzer
  1. New York

    The US Government Accountability Office, a regulatory watch-dog on federal government spending, is to investigate claims that the Food and Drug Administration attempted to silence one of its senior medical officers when he tried to warn that rofecoxib (Vioxx) caused heart attacks and strokes.

    The drug was withdrawn on 30 September by its manufacturers, Merck, after a study found a fourfold increase in serious thromboembolic adverse events in patients receiving rofecoxib compared with patients receiving placebo (BMJ 2004;329: 816, 9 Oct).

    David Graham, associate director for science in the FDA Drug Center's Office of Drug Safety, said that he was subjected to “veiled threats” …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular